Evidence map›Paper›PMID 33296042›Full record

ArticleEJNMMI research2020

Application of the PET ligand [

Mohammed Shahid, Juha O Rinne, Mika Scheinin, Jere Virta, Päivi Marjamäki, Olof Solin, Eveliina Arponen, Jukka Sallinen, Katja Kuokkanen, Juha Rouru

Open access · goldAbstract read
In one paragraph

Article in EJNMMI research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Mohammed ShahidOrion Corporation, Orion Pharma, Research and Development, Tengströminkatu 8, 20380, Espoo, Finland.
Juha O RinneTurku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.
Mika ScheininCRST, Turku, Finland.
Jere VirtaTurku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.
Päivi MarjamäkiTurku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.
Olof SolinTurku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.
Eveliina ArponenTurku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.
Jukka SallinenOrion Corporation, Orion Pharma, Research and Development, Tengströminkatu 8, 20380, Espoo, Finland.
Katja KuokkanenOrion Corporation, Orion Pharma, Research and Development, Tengströminkatu 8, 20380, Espoo, Finland.
Juha RouruOrion Corporation, Orion Pharma, Research and Development, Tengströminkatu 8, 20380, Espoo, Finland. juha.rouru@orionpharma.com.ORCID http://orcid.org/0000-0003-1520-2230
University of Turku · FIOrion Corporation (Finland) · FIÅbo Akademi University · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAvailability of the α

resultsORM-12741 has high affinity (K

conclusionsORM-12741 is a selective α

Indexed as

[11C]ORM-13070 PETBrain α2C-adrenoceptorsORM-12741Receptor occupancyα2C-Adrenoceptor antagonists

Identifiers

PMID33296042
PMCPMC7726058
OpenAlexW3111551670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.